Patents by Inventor Ioana Lovinger
Ioana Lovinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240041855Abstract: The subject invention provides a modified release solid oral dosage form comprising a therapeutically effective amount of Pridopidine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable rate controlling excipient, wherein the solid oral dosage form provides an in vivo plasma pridopidine concentration profile having a Mean Cmax of about 1,400 ng/ml or less. The subject invention also provides a method of treating an individual afflicted with a neurodegenerative disease or disease related to dopamine, comprising once daily administration of a modified release solid oral dosage form.Type: ApplicationFiled: October 23, 2023Publication date: February 8, 2024Applicant: Prilenia Neurotherapeutics Ltd.Inventors: Daniella LICHT, Ioana Lovinger, Laura Yehudit Guilatt, Merav Bassan
-
Patent number: 11452694Abstract: The subject invention provides a solid unit dosage form comprising pridopidine or pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the dosage form has a volume and wherein the ratio of the amount of pridopidine to the volume of the dosage form is 135-600 mg/ml.Type: GrantFiled: February 27, 2020Date of Patent: September 27, 2022Assignee: Prilenia Neurotherapeutics Ltd.Inventors: Danit Licht, Ioana Lovinger
-
Publication number: 20200188305Abstract: The subject invention provides a solid unit dosage form comprising pridopidine or pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the dosage form has a volume and wherein the ratio of the amount of pridopidine to the volume of the dosage form is 135-600 mg/ml.Type: ApplicationFiled: February 27, 2020Publication date: June 18, 2020Applicant: PRILENIA NEUROTHERAPEUTICS LTD.Inventors: Danit LICHT, Ioana LOVINGER
-
Publication number: 20190209542Abstract: The subject invention provides a modified release solid oral dosage form comprising a therapeutically effective amount of Pridopidine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable rate controlling excipient, wherein the solid oral dosage form provides an in vivo plasma pridopidine concentration profile having a Mean Cmax of about 1,400 ng/ml or less. The subject invention also provides a method of treating an individual afflicted with a neurodegenerative disease or disease related to dopamine, comprising once daily administration of a modified release solid oral dosage form.Type: ApplicationFiled: August 28, 2018Publication date: July 11, 2019Applicant: PRILENIA THERAPEUTICS DEVELOPMENT LTD.Inventors: Daniella Licht, Ioana Lovinger, Laura Yehudit Guilatt, Merav Bassan
-
Publication number: 20170065576Abstract: The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.Type: ApplicationFiled: November 17, 2016Publication date: March 9, 2017Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Vladimir Ioffe, Konstantin Ulanenko, Avital Laxer, Muhammad Safadi, Danit Licht, Ioana Lovinger, Ulf Tomas Fristedt
-
Publication number: 20170020854Abstract: This invention provides modified release solid oral dosage form comprising a therapeutically effective amount of pridopidine base, and at least one pharmaceutically acceptable rate controlling excipient.Type: ApplicationFiled: July 22, 2016Publication date: January 26, 2017Applicant: Teva Pharmaceuticals International GmbHInventors: Danit Licht, Ioana Lovinger, Muhammad Safadi
-
Publication number: 20160151345Abstract: The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.Type: ApplicationFiled: February 2, 2016Publication date: June 2, 2016Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Vladimir Ioffe, Konstantin Ulanenko, Avital Laxer, Muhammad Safadi, Danit Licht, Ioana Lovinger, Ulf Tomas Fristedt
-
Publication number: 20160151346Abstract: The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.Type: ApplicationFiled: February 2, 2016Publication date: June 2, 2016Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Vladimir Ioffe, Konstantin Ulanenko, Avital Laxer, Muhammad Safadi, Danit Licht, Ioana Lovinger, Ulf Tomas Fristedt
-
Patent number: 9340307Abstract: The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid, 1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3?-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide.Type: GrantFiled: September 20, 2013Date of Patent: May 17, 2016Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Muhammad Safadi, Daniella Licht, Ioana Lovinger, Aharon M. Eyal, Tomas Fristedt, Karl Jansson
-
Patent number: 9284276Abstract: The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.Type: GrantFiled: February 15, 2013Date of Patent: March 15, 2016Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Vladimir Ioffe, Konstantin Ulanenko, Avital Laxer, Muhammad Safadi, Danit Licht, Ioana Lovinger, Ulf Tomas Fristedt
-
Publication number: 20150202302Abstract: The subject invention provides a modified release solid oral dosage form comprising a therapeutically effective amount of Pridopidine or as pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable rate controlling excipient, wherein the solid oral dosage form provides an in vivo plasma pridopidine concentration profile having a Mean Cmax of about 1,400 ng/ml or less. The subject invention also provides a method of treating an individual afflicted with a neurodegenerative disease or disease related to dopamine, comprising once daily administration of a modified release said oral dosage form.Type: ApplicationFiled: January 21, 2015Publication date: July 23, 2015Applicant: IVAX INTERNATIONAL GMBHInventors: Daniella Licht, Ioana Lovinger, Laura Yehudit Guilatt, Merav Bassan
-
Publication number: 20140024678Abstract: The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5- chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4 -hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido) benzoic acid, 1H,3H-spiro[5-chloro-1-methylquinoline-2,4 -dione-3,3?-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4 -tetrahydro-quinoline-3-carboxamide.Type: ApplicationFiled: September 20, 2013Publication date: January 23, 2014Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Muhammad Safadi, Daniella Licht, Ioana Lovinger, Aharon M. Eyal, Tomas Fristedt, Karl Jansson
-
Publication number: 20140018386Abstract: The subject invention provides a stable pharmaceutical composition comprising a therapeutically effective amount of laquinimod, an amount of a filler, and an amount of a lubricant, wherein the stable pharmaceutical composition is free of an alkalizing agent or an oxidation reducing agent. Also provided are processes for making the stable pharmaceutical composition and sealed packages comprising the stable pharmaceutical composition. Also provided is a method for treating a subject afflicted with a form of multiple sclerosis (MS) or for alleviating a symptom of MS in a subject afflicted with a form of MS comprising administering to the subject a stable pharmaceutical composition as described herein. Also provided is use of a stable pharmaceutical composition as described herein for treating a subject afflicted with a form of MS or for alleviating a symptom of MS in a subject afflicted with a form of multiple MS.Type: ApplicationFiled: July 10, 2013Publication date: January 16, 2014Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Gadi Sarfati, Ioana Lovinger, Danit Licht, Muhammad Safadi
-
Patent number: 8545885Abstract: The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid, 1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3?-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide.Type: GrantFiled: May 14, 2012Date of Patent: October 1, 2013Assignees: Teva Pharmaceutical Industries, Ltd., Active Biotech, ABInventors: Muhammad Safadi, Daniella Licht, Ioana Lovinger, Aharon M. Eyal, Tomas Fristedt, Karl Jansson
-
Publication number: 20130217724Abstract: The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.Type: ApplicationFiled: February 15, 2013Publication date: August 22, 2013Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Vladimir Ioffe, Konstantin Ulanenko, Avital Laxer, Muhammad Safadi, Danit Licht, Ioana Lovinger, Ulf Tomas Fristedt
-
Publication number: 20120225124Abstract: The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid, 1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3?-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide.Type: ApplicationFiled: May 14, 2012Publication date: September 6, 2012Inventors: Muhammad Safadi, Daniella Licht, Ioana Lovinger, Aharon M. Eyal, Tomas Fristedt, Karl Jansson
-
Patent number: 8178127Abstract: The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid, 1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3?-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide.Type: GrantFiled: December 19, 2008Date of Patent: May 15, 2012Assignee: Teva Pharmaceuticals Industries, Ltd.Inventors: Muhammad Safadi, Daniella Licht, Ioana Lovinger, Aharon M. Eyal, Tomas Fristedt, Karl Jansson
-
Publication number: 20110301234Abstract: The invention relates to a pharmaceutical composition of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N?-propargyl-1-aminoindan ½ tartrate, at least one pharmaceutically acceptable excipient and up to 5% by weight of the composition of water. The composition is typically in a solid oral form which upon administration to a human subject provides a maximum blood plasma concentration of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N?-propargyl-1-aminoindan of at least 0.7 nmol/mL.Type: ApplicationFiled: August 17, 2011Publication date: December 8, 2011Inventors: Daniella Licht, Ioana Lovinger, Fanny Caciularu, Adrian Gilbert
-
Patent number: 8022104Abstract: Disclosed are formulations of ladostigil tartrate, including pharmaceutical compositions, process for the manufacture, and use thereof.Type: GrantFiled: February 24, 2006Date of Patent: September 20, 2011Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Technion Research and Development Foundation Ltd.Inventors: Daniella Licht, Ioana Lovinger, Fanny Caciularu, Adrian Gilbert
-
Publication number: 20090162432Abstract: The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid,1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3?-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide.Type: ApplicationFiled: December 19, 2008Publication date: June 25, 2009Inventors: Muhammad Safadi, Daniella Licht, Ioana Lovinger, Aharon M. Eyal, Tomas Fristedt, Karl Jansson